Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in IBD Patients Treated With Vedolizumab or Ustekinumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Gastroenterology and Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients With Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
Clin. Gastroenterol. Hepatol. 2020 Jul 12;[EPub Ahead of Print], A Hu, PG Kotze, A Burgevin, W Tan, A Jess, PS Li, K Kroeker, B Halloran, R Panaccione, L Peyrin-Biroulet, C Ma, AN AnanthakrishnanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.